<?xml version="1.0" encoding="UTF-8"?>
<p>TB remains one of the top ten causes of death in the world, and the source of major epidemics in developing countries [
 <xref rid="B65-vaccines-08-00036" ref-type="bibr">65</xref>]. Additionally, HIV-positivity is a contraindication for BCG vaccination, although these individuals are exponentially more likely to develop active TB [
 <xref rid="B56-vaccines-08-00036" ref-type="bibr">56</xref>,
 <xref rid="B65-vaccines-08-00036" ref-type="bibr">65</xref>]. Another threat to the eradication of TB is the increasing prevalence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) [
 <xref rid="B65-vaccines-08-00036" ref-type="bibr">65</xref>]. Efforts have continued to reach milestones that were established by the WHOâ€™s End TB strategy, but the current trajectory of TB decline will not meet previous deadlines [
 <xref rid="B65-vaccines-08-00036" ref-type="bibr">65</xref>]. Although BCG LAV plays an essential role in eradicating TB, new and effective vaccine strategies are now urgently needed. 
</p>
